Expansion opportunity Prospection has demonstrated growth through international expansion, including opening offices in Japan and broader Asia, signaling potential needs for regionalized sales approaches, localized regulatory considerations, and cross-border partnerships.

Board enhancements Recent appointments to the board including non-executive directors with technology and pharma expertise suggest a readiness to strengthen governance, strategic oversight, and potential collaboration on high-value deals and long-term contracts.

AI driven value The Patient-centric Intelligence Core underpins AI-forward products and enriched data offerings, presenting sales opportunities around advanced analytics, real-world evidence, and decision-support solutions for commercial, medical, and analytics teams.

Strategic partnerships With a track record across 100+ indications and 20+ therapeutic areas and a history of partnerships with 100 life sciences companies, there is a strong signal for scaling partnerships, co-development, or data collaboration projects.

Growth funding A series B funding round and continued headcount growth indicate ongoing investment, creating openings for upsell of data services, platform licenses, and consulting engagements to capitalize on expanding capabilities.